Boots to begin prescribing medical cannabis in UK

by | Nov 16, 2026 | Business

Boots to begin prescribing medical cannabis in UK

Boots has announced the launch of SureLeaf, an online medical cannabis prescribing service available to UK patients aged 25 and older with qualifying conditions including chronic pain, anxiety, and insomnia. The service represents a first for a major high street pharmacy in the country.

Patients interested in the service will begin with an online assessment, followed by clinical review and a video consultation with a consultant. All prescriptions will undergo independent review by a multidisciplinary team including a second consultant before treatment commences. Boots stated that patients must have attempted conventional treatments without adequate relief before becoming eligible for medical cannabis, with ongoing monitoring and reviews required throughout treatment.

The pharmacy is partnering with the University of Nottingham on a collaborative research program designed to evaluate patient outcomes, prescribing patterns, and treatment experiences related to chronic pain management. Jamie Kerruish, Boots’ chief healthcare officer, emphasized that the service aims to help patients explore options for managing symptoms when conventional approaches prove insufficient.

Dr David Gwynne, medical director of the online service, noted that medical cannabis is not appropriate for all patients and stressed that prescribing decisions require careful individual assessment with strong clinical safeguards and specialist oversight at each stage. Medical cannabis prescription was legalized in 2018 following a high-profile case involving a child with severe epilepsy. Currently, NHS prescribing remains limited to specific conditions including certain forms of epilepsy, chemotherapy side effects, and particular multiple sclerosis symptoms, while private clinics have treated patients with various psychiatric and neurological conditions using cannabis-derived medicines for several years.

Recent research from Australian and English universities identified limited evidence supporting cannabis effectiveness for anxiety, anorexia nervosa, psychotic disorders, post-traumatic stress disorder, and opioid use disorder, though some evidence supported its use for cannabis dependence, Tourette syndrome symptoms, and insomnia.

Article Attribution | Read More at Article Source

Article summary produced by Claude AI